PTAB rejects IPR challenges to Gilead patents
14-06-2018
PTAB invalidates Johnson & Johnson cancer drug patent
18-01-2018
olm26250 / iStockphoto.com
Biotechnology company Qiagen has failed in its bid to stop diagnostics company HandyLab from retaining a patent for a diagnostic system, according to a decision issued by the US Patent Trial and Appeal Board on Tuesday, July 14.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
HandyLab, Qiagen, PTAB, Biotechnology, NeuMoDx, Becton, Dickinson & Co,, diagnostics, diagnostic system, patent, Delaware
